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ABSTRACT
The number of studies on public expenditure is growing in view of the growing 
importance of the evaluation of drug policies. Public expenditure is an important 
indicator of government efforts to tackle the drug problem. 
Studying public expenditure and comparing the methodology and the results of 
existing research is challenging. In the present article, the concepts and methodologies 
used in studies of public expenditure are reviewed. Public expenditure and social cost 
models are compared to determine their scope. The possibilities and limitations of 
studying drug budgets are discussed. A workable methodology for estimating public 
expenditure on drugs is proposed. 
Introduction
Since the 1990s, the evaluation of drug policy and policy programmes has become 
increasingly important in western societies. An essential step in the evaluation 
of drug policy is the estimation of public expenditure, since that makes it pos-
sible to evaluate the commitments of governments in the field of drug policy. 
 Canada and the United States of America have a long tradition of studying 
public expenditure on drugs [1-9]. Since the start of the decade of the 2000s, 
the importance of this research theme has been increasingly recognized by 
researchers and policymakers in Europe as well [10, 11]. The European Union 
action plan on drugs for the period 2000-2004 stated that evaluation was to be 
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an integral part of the European approach to the drug phenomenon and that 
the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
should be an important contributor to that evaluation. Since 2001, EMCDDA 
has underlined the importance of studies on public expenditure on drug policy 
in States members of the European Union. In the most recent European Union 
action plans on drugs, for the periods 2005-2008 and 2009-2012, the estimation 
of public expenditure became one of the special points of interest.
 The first European studies on public expenditure on drugs were published 
in Sweden [12] and Luxembourg [13]. Since then, studies have followed in the 
Netherlands [14], Belgium [15, 16], France [17] and Germany [18]. Parallel to 
the studies of national public expenditure, some studies have tried to compare 
public expenditure on drugs in all European Union member States [19, 20]. In 
2004, Reuter, Ramstedt and Rigter proposed guidelines for the estimation of 
public expenditure on drug policy throughout the European Union [21].
 Studying public expenditure, in particular comparing the methodology and the 
results of existing studies conducted in different countries of the European Union, 
is challenging. The existing studies use differing definitions of public expenditure, 
and consequently, the object of analysis and the methodology applied differ. 
 The aim of the present article is to untangle the existing confusion with 
regard to public expenditure studies in the European Union. To that end, this 
article reviews the concepts and methodologies used in studies on European 
public expenditure on drug policy. Such an undertaking might stimulate the 
development of evidence-based policies in the European Union. 
Method
The objective of the present article is to clarify the concept of public expenditure 
and examine existing methodologies used to calculate public expenditure on drug 
policy in the European Union. To that end, European studies dealing with the 
estimation of public expenditure were searched for by consulting search engines 
and online scientific databases. The databases of the Web of Science, PubMed and 
Sociological Abstracts were consulted. In addition, the websites of EMCDDA and 
the World Health Organization were searched. The terms “public expenditure”, 
“public expenditure study”, “public expenditure drugs”, “public expenditure on 
drug policy”, “budget”, “spending”, in combination with the terms “drugs” and 
“substances”, were used to screen the databases. Time periods were not deter-
mined. The focus was placed on studies estimating public expenditures in Euro-
pean countries. 
 The search resulted in the identification of 10 studies on public expenditure 
[12-21]. Table 1 presents an overview of the studies reviewed in this article.
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Results 
On the basis of the review of European public expenditure studies, it is clear 
that there is no common understanding of the meaning of “public expenditure” 
in the European Union. Very different concepts are used interchangeably, or the 
same terminology is used but with definitions and interpretations that can differ 
widely [20].
Definition of public expenditure in reviewed studies in Europe
The drug phenomenon is multidimensional, consisting of many aspects ranging 
from health (e.g. epidemiology, prevention and treatment) and legal problems, 
drug-related crime and security issues (e.g. use of drugs in traffic and drug- 
related public nuisance) to economic problems (e.g. loss of productivity and 
absenteeism in the workplace). All these different problems bear costs for the 
individual and the community [15]. A part of those costs is borne by the pub-
lic authorities responsible for the different policy areas in the field of drugs. The 
key element in public expenditure is the financial contribution of public 
authorities to drug policy [13, 16, 17]. European studies on public expenditure 
use different concepts and definitions to define the term “public expenditure”. 
In order to compare public expenditure studies throughout Europe, it is impor-
tant to be clear about the conceptual framework used. It is equally important 
to define which areas of expenditure lie within and outside the scope of a given 
public expenditure study. This implies that a public expenditure analysis 
proceeds from the perspective of the different public authorities that are com-
petent for the respective aspects of the drug policy [16, 20].
 Kopp and Fenoglio [17] and Origer [13] refer to expenditure emanating from 
the public authorities and used for the different policy sectors of the drug policy 
(law enforcement, treatment, prevention).
 Kopp and Fenoglio and De Ruyver and others define the term “drug budget” 
as being synonymous with public expenditure on drug policy [16, 19, 22]. The 
drug budget of the public authorities at each different level of competency is 
analysed. European States are characterized by their various State structures, and 
those authors stress the importance of taking into account the different levels 
of competence (national, regional and local) in estimating public expenditure, 
because in each country the division of areas of competence in the field of drug 
issues differs and is spread over different policy domains (epidemiology, preven-
tion, treatment, law enforcement). Given the different State structures of France 
and Germany, for instance, we would not be able to compare the public 
expenditure of those two countries if we count only expenditure stemming from 
the national Government. 
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 The key criterion in determining what counts as public expenditure for drug 
policy is whether the expenditure is directly related to drug policy actions [12, 
13, 15, 16, 20]. Such expenditure can be described as investments or budget lines 
of public authorities for actions expressly and directly aimed at implementing 
drug policy. Postma states that public expenditures are a part of the “direct costs 
such as expenditures on prevention, research, treatment, rehabilitation, law 
enforcement and cost of illness” [20, p. 9]. Ramstedt defines public expenditure 
as “specific expenditures” or “expenditures directly related to actions targeted at 
some drug-related consequences or […] prevention” [12, p. 330]. Origer excludes 
the indirect costs and the costs of indirect consequences and defines public 
expenditures as direct costs only [13]. De Ruyver and others refer to “expenditures 
expressly and directly labelled for drug policy actions” [16, p. 5].
 Consequently, expenditures related to the consequences of drug use are 
excluded in most European public expenditure studies [13, 15, 16, 17]. Those 
excluded expenditures are referred to as “external expenditures”. Two categories 
of external expenditure are distinguished: (a) external expenditure that is not 
explicitly aimed at drug policy actions but that indirectly supports the drug 
policy (e.g. expenditure on drug-related crime such as theft, and spending on 
drug-related treatment such as treatment of infections contracted through use of 
contaminated needles); and (b) external expenditure arising from loss of produc-
tivity and absenteeism in the workplace.
 Some authors, however, include a certain degree of external expenditure. 
Ramstedt and Rigter, both as cited in Reuter, Ramstedt and Rigter (2004), and 
Postma (2004) include specific consequences of the drug problem [20, 21]. Postma 
includes the cost of illness for drug-related diseases (such as infections, heart 
disease, retroviruses and mental disorders) in his analysis. In the studies of 
Ramstedt (2004) and Rigter (2004), expenditures relating to the consequences 
ofthe drug problem are limited to drug-related crime such as theft, robbery and 
traffic offences, and treatment [12, 14]. Ramstedt explicitly states that in addition 
to the estimation of “specific expenditures”, he also considers “a broader definition 
of costs where expenditures not specifically defined as drug-related but nevertheless 
connected to the drug policy are taken into account (e.g. other criminality or 
morbidity among drug abusers)” [12, p. 330].
 Obviously, comparisons between studies including external expenditures and 
studies not including external expenditures are meaningless if the studies of the 
former group do not clearly indicate the amount of such expenditure. 
 The concept of external expenditure is not always presented in studies. Such 
studies may refer rather implicitly to external expenditure by stating that the 
various governmental agencies and the drug budget spent by public authorities 
are the key elements of public expenditure and that consequently, expenditure 
that goes beyond calculating the drug budget is excluded [12, 14, 19, 21]. 
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 In line with the definition of public expenditure, private expenditure is 
excluded from studies of public expenditure. Private expenditure is the spending 
of individuals and private organizations, such as the expenditure of drug users 
and the expenditure of charity funds [14-16]. 
 In studies of public expenditure in Europe, public expenditure is partly 
defined by distinguishing public expenditure analysis from social cost analysis. 
Public expenditure is one element of the social cost of the drug problem. The 
sum of public expenditure, private expenditure and external expenditure consti-
tute the total social cost of drugs in society (see table 2) [13, 15-17, 22, 23].
Table 2.  Concept of public expenditure
Public expenditure + Private expenditure + External expenditure = Social cost
Direct expenditure by 
public authorities on drug 
policy actions, e.g. 
street-corner work, 
prevention work, drug 
treatment, guidance for 
drug users, reintegration 
programmes (employ-
ment) for (former) drug 
users, expenditure for 
personnel such as police 
officers working in drug 
investigation units, 
customs officers special-
ized in detecting drug 
trafficking and magis-
trates dealing with drug 
cases, expenditure for 
drug coordinators, 
expenditure on research, 
annual financial contribu-
tions to the Pompidou 
Group of the Council of 
Europe.
Expenditure of 
individuals and 
private organiza-
tions, e.g. expendi-
ture of drug users, 
expenditure by 
private organizations 
not subsidized by 
public authorities 
and expenditure of 
charity funds.
Expenditure related 
to the consequences 
of drug use,  
e.g. expenditure on 
drug-related 
nuisance, drug- 
related crime such as 
theft, robbery, traffic 
offences committed 
by drug users, 
expenditure on the 
treatment of 
infections due to 
contaminated 
needles, treatment 
of illness contracted 
through drug use, 
such as AIDS and 
hepatitis, expendi-
ture due to loss of 
productivity, absen-
teeism in the 
workplace.
Total 
expenditure 
on the drug 
problem at 
the expense 
of the 
community.
Methodological frameworks used in the European studies reviewed 
The following section describes the various methodological steps taken to estimate 
public expenditure, drawing on the studies reviewed. As shown, the methodologi-
cal steps taken and choices made vary from study to study.
Step I. Defining the research scope
In the public expenditure studies reviewed, the scope of research is limited to 
illicit drugs, with the single exception of the study of Kopp and Fenoglio (2006), 
which also focuses on alcohol and tobacco [17]. 
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 There are good arguments for broadening the scope of research to include 
licit drugs in public expenditure studies [24]. First, the drug phenomenon is 
considered a health problem. The distinction between legal and illegal drugs is 
relevant only from a juridical-criminological point of view. Second, with respect to 
calculating the total cost of drugs to society, studies show that, for the greater 
part, costs are related to the alcohol problem, followed by tobacco and, finally, by 
illicit drugs [23, 25, 26, 27].
Step II. Identifying the major players responsible for drug policy
In a public expenditure study, insight is needed into where the expenditure stems 
from. To that end, the major players involved in drug policy have to be identified.
 Thus, the public authorities competent for aspects of the drug policy are 
identified. This is important since the specific State and governmental structure 
in each country differs [15, 16, 19]. The reviewed studies take into account the 
specific State and governmental structure and analyse expenditure on drug 
policy by the different public authorities responsible for the policy areas. 
 In addition to the identification of the public authorities involved in drug 
policy, the organizations working in the drug field can also be identified. Once 
those organizations are identified, information can be collected on the financial 
means of the private (non-governmental) organizations and public organizations 
and the public authority responsible for their payment. The studies of Kopp and 
Fenoglio (2003) and De Ruyver and others are the only ones to identify those 
organizations [15, 16, 19]. 
Step III. Collection of data: top-down and bottom-up approaches
Once the sources of the expenditure are known, one can start collecting data 
on budgets. To do so, two methods of analysis are used: a top-down approach 
and a bottom-up approach. The top-down approach starts with the resources 
or overall budgets made available by the various public authorities involved in 
the drug policy. Data on the public authorities’ drug budgets are collected, and 
the budget lines of the public administrations are analysed [15, 16, 20]. The 
top-down approach has the advantage of not relying on secondary data: the 
budgets can be retrieved and analysed directly. 
 The bottom-up approach starts with the activities carried out in the work 
field and traces the money flow back to the funding from public authorities. 
Data are examined on the basis of the means of the private (non-governmental) 
organizations and public organizations and yearly reports, complemented by 
questionnaires and interviews with those organizations [15, 16]. The bottom-up 
approach allows for a detailed identification of the existing activities in the work 
field and the public authority responsible for payment.
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 The advantage of combining the top-down and bottom-up approaches is that 
it makes verification possible: the data gathered using the top-down approach 
can be double-checked and completed with the data retrieved from the project 
actors in the field. 
 Most public expenditure studies apply a top-down approach. The only study 
that is exclusively bottom-up is the study of Kopp and Fenoglio (2003) [19]. 
The Belgian studies of De Ruyver and others are the only studies that combine 
both approaches [15, 16].
Step IV. Classification of public expenditure
The classification of expenditure is needed in order to gain insight into the 
sources and the purpose for which the expenditure is intended [21]. 
 As is the case with the definition of public expenditure, differences were 
found in the studies reviewed with regard to classification according to drug 
policy sectors.
 In the public expenditure studies of Ramstedt (2004), Rigter (2004) and 
Reuter, Ramstedt and Rigter (2004), expenditure is classified according to the 
conventional drug policy areas or sectors: “prevention”, “treatment”, “harm reduc-
tion” and “law enforcement” [12, 14, 21]. Postma (2004) makes use of the sectors 
of prevention, treatment and enforcement but creates an additional sector: the cost 
of illness [20]. In the study of Kopp and Fenoglio (2003), the only distinction is 
between expenditure related to health care and that related to law enforcement 
[19]. The studies of Origer and Mostardt and others do not classify expenditure 
according to the conventional drug policy areas [13, 18]. Origer classifies public 
expenditure using the categories of spending for demand reduction and that for 
harm reduction, expenditure for supply-side reduction, expenditure for research 
and expenditure for the European Union drug budget [13]. Mostardt and others 
use the Classification of the Functions of Government (COFOG) classification  and 
therefore make a distinction between general public services, public order and 
safety, health and social protection [18].
 In the studies of De Ruyver and others, expenditure on harm reduction is not 
presented as an independent sector but is allocated to the sector of “treatment” 
[15, 16]. Rigter (as cited in Reuter, Ramstedt and Rigter (2004)) underlines that 
harm reduction is difficult to define and that some policy actions included in the 
sectors of prevention and treatment overlap with the harm reduction sector [21]. 
Moreover, it is not always feasible to separate harm reduction aspects from a treat-
ment programme [28]. This is, for instance, the case for low-threshold methadone 
 *Classification of the Functions of Government (COFOG) is a detailed classification of functions or 
socio-economic objectives that general government units aim to achieve through a range of outlays. COFOG 
is used for making international comparisons within the European Union.
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maintenance programmes. A political reason for not studying a harm reduction 
sector separately may be found in the drug policy aims or intentions of the public 
authorities. In the drug budget of Sweden, for example, no data on harm reduction 
as such are available since the goal of a drug-free society is being pursued, and 
consequently, harm reduction as an outcome is explicitly rejected [29]. Nonethe-
less, this does not imply that specific harm reduction programmes are non-existent.
 Reuter, Ramstedt and Rigter (2004) suggest that it could be useful to split 
up the conventional sectors into narrower categories, and they point to expend-
iture on law enforcement, where distinctions can be made between the different 
levels of the criminal justice system [21]. The two Belgian studies of De Ruyver 
and others present the results of expenditure on law enforcement according to 
the different levels of the criminal justice system [15, 16]. All the other studies 
reviewed contain data collected on expenditure at the different levels of the 
criminal justice system but do not present the results separately. 
 Some expenditure cannot be attributed to a conventional policy sector because 
the purpose of the expenditure does not correspond to any of those sectors 
[15, 16, 29]. In the Belgian study of De Ruyver and others (2007), the category 
of “other” is created. This is merely a miscellaneous sector designated for 
expenditure that cannot be classified under the conventional sectors. Examples 
are expenditure for drug coordinators and expenditure on non-sector-related 
research and policy [16]. 
 Studies also differ with respect to the classification of similar expenditures 
in different policy sectors. Kopp and Fenoglio (2003) point out that treatment 
of detainees may be classified under treatment in one country and under law 
enforcement in another [19]. In the study of Rigter (2006), expenditure on treat-
ment programmes for drug users in prison is classified as belonging to the sector 
of treatment [30]. In the other reviewed studies, it is not explicitly indicated 
whether prison-based treatment is allocated to the sector of treatment or the 
sector of law enforcement. Rigter (as cited in Reuter, Ramstedt and Rigter (2004)) 
refers to expenditure on social cohesion and public safety [21]. This expenditure 
is intended to protect the community against nuisance caused by drug users 
and drug dealers. Rigter classified this expenditure under the sector of treatment 
although he acknowledges that such spending could have been classified as law 
enforcement. The starting point for deciding to which sector expenditure should 
be allocated is to determine the intended purpose of that expenditure. Following 
this line of reasoning, expenditure on the treatment of detainees should be 
allocated to the sector of treatment.
Step V. Calculating the data
The vast majority of expenditure intended for illicit drugs is embedded in 
expenditure intended for broader policy domains. Kopp and Fenoglio found that 
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90 per cent of the drug budget in the European Union reflects spending by bodies 
not specialized in the drug issue [23]. 
 Some expenditure is exclusively used for initiatives on illegal drugs, e.g. syringe-
exchange programmes. To estimate such expenditure, no additional calculation is 
needed, as the results obtained are drug-specific forms of expenditure. 
 Because public expenditure on drug policy is often embedded in policy projects 
with broader objectives, it is important to look beyond the expenditure used 
exclusively for drug policy and include spending intended for broader policy domains. 
For example, in the budget of the Ministry of Justice, the expenditure component 
intended for dealing with drug offences has to be isolated from the total budget 
spent on the criminal justice system [19, 23]. In this respect, EMCDDA refers to 
“labelled” and “non-labelled” expenditure [31].
 All the reviewed studies attempt to estimate these two types of public expend-
iture. Nevertheless, all studies emphasize the difficulty in calculating expenditure 
that is embedded in a broader budgetary structure. 
 The application of repartition keys is needed to isolate spending embedded 
into a broader budgetary structure. Kopp and Fenoglio point out that there is 
no general methodology to determine repartition keys. Determination of the 
repartition key depends on the case (on the basis of information from registra-
tion systems, annual reports, contacts with the work field, etc.) [32]. Use of a 
repartition key is required, for instance, in the case of health promotion. To 
isolate public expenditure on illicit drugs in this budget, the number of projects 
for the prevention of illicit drug use is divided by the total number of prevention 
projects. This calculation produces a percentage that reflects the proportion of 
projects designated for illicit drugs. However, when estimating expenditure on 
all drugs, regardless of their legal status, a repartition key is no longer needed 
in the case of health promotion. Another example of where the use of a repar-
tition key is needed is in estimating the expenditure on enforcement by police, 
judicial and customs authorities. The repartition key can be formulated as the 
fraction of the total number of offences that are offences related to violations of 
drug laws. For example, in the study of De Ruyver and others (2007), the drug-
related expenditure of the local police in the sector of enforcement is calculated 
as follows [16]: 
total budget of local police x
number of registered  
“narcotic substance” offences
number of all registered offences
In this case, the total budget of the local police is multiplied by the repartition 
key, namely, the fraction of total registered offences that are drug-related 
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registered offences. The result of this formula gives us the public expenditure 
made by the local police with respect to drug policy. In this method, the propor-
tion of working hours of police staff devoted to criminal cases has to be calcu-
lated in order to determine the proportion of working hours spent on violations 
of drug laws [15, 16, 23]. The repartition key method ensures that all resources 
deployed—personnel, overhead, equipment and operation—are taken into account 
[33]. A disadvantage of this method is that it implicitly assumes that the 
expenditure per unit of activity is the same for all activities (e.g. the expenditure 
related to a drug user is equal to the expenditure for other clients and the 
expenditure for a drug case is equal to the expenditure for cases of other types). 
Differences in the expenditure per unit of activity are ignored [12, 21]. It is 
therefore essential to study whether the investment in terms of working hours 
for the treatment of drug users and other clients is comparable [16].
 In some cases, it is impossible to apply a repartition key as no detailed data on 
budgets are available. In such cases, a calculation on the basis of unit expenditure 
is required [16]. This type of calculation is used, for example, in studies to measure 
public expenditure for the hospitalization of drug users in a non-drug-specific service. 
The average expenditure for hospitalization per day is multiplied by the average 
number of days a drug user is hospitalized. However, this method should be used 
with caution, since the researcher, in order to determine a unit expenditure, has to 
depend on the institutions/actors involved, leading to a possible contestation of the 
reliability of the data. Secondly, the determination of unit expenditure is restricted 
to spending on personnel.
 All the studies reviewed make use of repartition keys to estimate expenditure 
intended for broader policy domains. When no detailed data are available, stud-
ies fall back on the use of unit expenditure. Both methods have disadvantages, 
and therefore the results can be treated only as estimates of public expenditure. 
Discussion
Research into public expenditure in Europe is gaining momentum, in view of the 
growing realization of the importance of the evaluation of drug policy. Public 
expenditure is an indication of the resources dedicated by government to drug 
policy and shows whether a Government’s priorities for that drug policy are 
reflected in the corresponding budget. The study of drug budgets does not enable 
researchers to draw conclusions about the level (or change in the level) of drug 
consumption in a given region or country. Rather, they inform us of the priorities 
that a Government has set. A drug budget provides insight into the level of 
public expenditure in the drug field and into the composition of those expendi-
tures, in other words, the so-called “policy mix” decided on by the public 
authorities. Consequently, the prevailing balance between the various sectors of 
illicit drug policy (prevention, treatment and law enforcement) also becomes 
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visible. In the Belgian Federal Drug Policy Note of 2001, for example, prevention 
is said to be the priority in drug policy, followed by treatment and, as a last resort, 
law enforcement. In fact, with regard to public expenditure, the opposite became 
clear from the public expenditure studies: the most substantial expenditures relate 
to law enforcement, followed by treatment and then prevention [15, 16]. 
 Furthermore, a comparison of the drug expenditures of different countries 
could be of use to a Government. For example, the performance of a drug pol-
icy can be improved if the treatment expenditures per problematic drug user are 
too high in comparison with the corresponding amount in other countries [28]. 
 The results of public expenditure studies can thus be used to modify or 
rationalize public expenditure. Research into public expenditure is an important 
element to meet the requirements of an evidence-based policy, and it is the first 
step towards cost-effectiveness research. A precise estimate of public expenditures 
will enable Governments to use their drug budget more effectively to implement 
strategies [3]. 
 The methodology necessary to study public expenditure on drugs is complex 
because different policy areas (prevention, treatment and law enforcement) and 
different levels of government (local, regional and federal) are involved. Ideally, 
two methods of analysis are combined: a top-down approach analysing the fund-
ing sources of the private and public organizations and a bottom-up approach 
analysing the activities in the work field. To calculate public expenditure, a 
distinction has to be made between explicitly labelled drug-related expenditure 
and expenditure not labelled as drug-related. 
 The study of public expenditure has some important limitations. First, 
the quality of public expenditure studies is only as good as the quality and 
time liness of the available data. For instance, the study of Rigter (2006) calcu-
lates the drug policy spending in the Netherlands in 2003 [30]. The estimates 
of drug expenditures on public prosecution, courts and detention are based 
partly on old data. The author uses the share of offences under the Opium Act 
in the total number of cases leading to detention verdicts in courts, although 
the registration of those Opium Act offences is from the period 1997–2001. 
 Second, a drug budget is a fragile construction that is liable to variance 
depending on calculation method. The importance of using a single, clear meth-
odology applied in a uniform manner cannot be stressed enough, particularly 
when the comparison of different time periods or, especially, of different countries 
is the aim [3]. A small change in methodology (e.g. a change in the qualification 
or in a repartition key) might ultimately lead, through a misinterpretation of 
the change in results, to a decision to increase or decrease public expenditure, 
even though there was no actual change in the drug budget [34]. For example, 
between their first study (2004) and the second study (2007), De Ruyver and 
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others changed their methodology for estimating public expenditures for law 
enforcement [15, 16]. In the 2007 study, expenditures were no longer limited to 
personnel costs, as costs for investment and functioning were taken into account, 
making the results more accurate. Consequently, public expenditure for law 
enforcement appeared to increase by 64 per cent over a period of two years. But 
the reported increase was owing to the change in methodology, not an actual 
increase in the public expenditures.
 Third, two types of public expenditure exist: spending used exclusively for 
drug policy and expenditure intended for broader policy domains. To calculate 
the expenditure on drug policy contained in a general budget (which is where 
approximately 90 per cent of the total drug budget is contained), it is necessary 
to apply a repartition key to the obtained amount or make a unit expenditure 
calculation. Both methods have disadvantages, and therefore the results can be 
no more than estimates of the public expenditure. In particular, the use of a 
unit expenditure should be used with caution, since in order to determine unit 
expenditure, the researcher has to rely on the data provided by institutions/
actors involved, leading to a possible contestation of the reliability of the data. 
 Furthermore, public expenditure studies do not allow for a full policy evalu-
ation. These studies are, in themselves, not a quality measurement of policy. To 
achieve policy evaluation, an elaborated plan is needed, with clear statements on 
goals, operational action points, budgets and time frames. Ideally, the policy plan 
should be evidence-based, that is, based on epidemiological data about new trends 
in drug use and groups of drug users, including problem drug users, on data about 
target groups insufficiently reached by prevention, early intervention and treatment 
efforts and data on evaluation and effectiveness studies. 
 Finally, studying public expenditure, especially for a delicate subject such as 
drugs, is potentially hazardous [35]. Public authorities are markedly interested 
in and concerned about the results of studies of this type. They want the results 
to be positive, that is, to show that they are investing a substantial amount 
of government funds in the drug policy priorities that they want to achieve. 
Conversely, they do not want to invest in policy areas that they do not want the 
drug policy to be associated with. The latter is clear in the example of Sweden, 
where harm reduction strategies, although they exist in the country, were not 
separately reported in the budget’s results. 
 Public expenditure studies are mostly initiated and financed by public 
authorities; that situation requires researchers to maintain scientific rigour in 
the execution and presentation of the results of those studies. Therefore, the 
EMCDDA initiative of developing a uniform methodology for calculating the 
public expenditures of all European Union member States is laudable. 
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